Overview

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
To compare the pharmacokinetic profile of the proposed extended- release tablet of naproxen sodium 660 mg relative to two tablets of Naprelan 500 mg following single dose administration for 36 hours under fasted conditions
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Naproxen